Quantum Cyber (QUCY) Registration Filing summary

Company overview and business model

• Develops and sells in-vitro diagnostic (IVD) tests for early cancer detection, with a focus on colorectal and pancreatic cancer.

• Flagship product, ColoAlert, is CE-IVD certified and marketed in Europe; next-generation mRNA-based CRC screening test in development for US and EU launch.

• Pursues partnerships with labs and technology firms to expand market reach and enhance product development.

• Engaged in R&D projects, including PancAlert for pancreatic cancer, leveraging proprietary and licensed biomarkers.

Financial performance and metrics

• Early revenue stage with ongoing operating losses since inception; profitability timeline uncertain.

• Market value of outstanding ordinary shares held by non-affiliates as of December 5, 2025, was approximately $14.8 million.

• $4.9 million of securities sold in the 12 months prior to the filing.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for working capital purposes.

• More detailed allocation and milestones to be provided in future prospectus supplements.